Effect of strict glycemic control in patients with diabetes mellitus on frequency of macrovascular events

American Journal of Cardiology

Volumn 112, Issue 7, 2013, Pages 1033-1038

  Singh, Amita ^a   Donnino, Robert ^a,b   Weintraub, Howard ^a   Schwartzbard, Arthur ^a,b  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EXENDIN 4; GLIPIZIDE; HEMOGLOBIN A1C; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; MEGLITINIDE; METFORMIN; NATEGLINIDE; PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE C; ROSIGLITAZONE; SULFONYLUREA; VALSARTAN;

ACUTE CORONARY SYNDROME; AMPUTATION; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIABETIC PATIENT; DIET RESTRICTION; DISEASE COURSE; EARLY INTERVENTION; ENZYME PHOSPHORYLATION; FOLLOW UP; GLYCEMIC CONTROL; HEART DEATH; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; LIFESTYLE MODIFICATION; LONG TERM CARE; MICROANGIOPATHY; MORBIDITY; MORTALITY; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; RETINOPATHY; REVASCULARIZATION; REVIEW; RISK FACTOR; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE AGGREGATION; UNITED STATES; VASCULAR DISEASE; WEIGHT REDUCTION;

DIABETES MELLITUS; DIABETIC ANGIOPATHIES; HUMANS; HYPOGLYCEMIC AGENTS; PATIENT CARE PLANNING;

EID: 84884413740     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2013.05.044     Document Type: Review

References (53)

1. American Diabetes Association Standards of medical care in diabetes - 2013 Diabetes Care 36 Suppl 1 2013 S11 S66
2. C.C. Cowie, K.F. Rust, E.S. Ford, M.S. Eberhardt, D.D. Byrd-Holt, C. Li, D.E. Williams, E.W. Gregg, K.E. Bainbridge, S.H. Saydah, and L.S. Geiss Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006 Diabetes Care 32 2009 287 294
3. Centers for Disease Control and Prevention National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011 2011 U.S. Department of Health and Human Services, Centers for Disease Control and Prevention Atlanta 1-12
4. N.J. Morrish, S.L. Wang, L.K. Stevens, J.H. Fuller, and H. Keen Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes Diabetologia 44 Suppl 2 2001 S14 S21
5. P. Gaede, H. Lund-Andersen, H.H. Parving, and O. Pedersen Effect of a multifactorial intervention on mortality in type 2 diabetes N Engl J Med 358 2008 580 591
6. American Diabetes Association Standards of medical care in diabetes - 2012 Diabetes Care 35 Suppl 1 2012 S11 S63
7. F.B. Hu, M.J. Stampfer, S.M. Haffner, C.G. Solomon, W.C. Willett, and J.A.E. Manson Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes Diabetes Care 25 2002 1129 1134
8. E.J. Brunner, M.J. Shipley, D.R. Witte, J.H. Fuller, and M.G. Marmot Relation between blood glucose and coronary mortality over 33 years in the Whitehall study Diabetes Care 29 2006 26 31
9. K.T. Khaw, N. Wareham, R. Luben, S. Bingham, S. Oakes, A. Welch, and N. Day Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk) BMJ 322 2001 15 18
10. E. Selvin, S. Marinopoulos, G. Berkenblit, T. Rami, F.L. Brancati, N.R. Powe, and S.H. Golden Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus Ann Intern Med 141 2004 421 431
11. G. Basta, A.M. Schmidt, and R. De Caterina Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes Cardiovasc Res 63 2004 582 592
12. J.A. Beckman, A.B. Goldfine, M.B. Gordon, L.A. Garrett, and M.A. Creager Inhibition of protein kinase Cbeta prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans Circ Res 90 2002 107 111
13. I. Mertens, and L.F. Van Gaal Obesity, haemostasis and the fibrinolytic system Obes Rev 3 2002 85 101
14. A. Prasad, P. Bekker, and S. Tsimikas Advanced glycation end products and diabetic cardiovascular disease Cardiol Rev 20 2012 177 183
15. M. Morita, S. Yano, T. Yamaguchi, and T. Sugimoto Advanced glycation end products-induced reactive oxygen species generation is partly through NF-kappa B activation in human aortic endothelial cells J Diabetes Complications 27 2013 11 15
16. F. Cosentino, K. Hishikawa, Z.S. Katusic, and T.F. Luscher High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells Circulation 96 1997 25 28
17. C.J. Rodriguez, Y. Miyake, C. Grahame-Clarke, M.R. Di Tullio, R.R. Sciacca, B. Boden-Albala, R.L. Sacco, and S. Homma Relation of plasma glucose and endothelial function in a population-based multiethnic sample of subjects without diabetes mellitus Am J Cardiol 96 2005 1273 1277
18. M. Brownlee The pathobiology of diabetic complications: a unifying mechanism Diabetes 54 2005 1615 1625
19. G.L. Pierce Targeting vascular endothelial cell insulin resistance in type 2 diabetes mellitus: is protein kinase C-beta the bullseye for reducing vascular risk in diabetes? Circulation 127 2013 16 18
20. I. Gabriely, X.M. Yang, J.A. Cases, X.H. Ma, L. Rossetti, and N. Barzilai Hyperglycemia induces PAI-1 gene expression in adipose tissue by activation of the hexosamine biosynthetic pathway Atherosclerosis 160 2002 115 122
21. K. Hara, K. Omori, Y. Sumioka, and Y. Aso Spontaneous platelet aggregation evaluated by laser light scatter in patients with type 2 diabetes: effects of short-term improved glycemic control and adiponectin Transl Res 159 2012 15 24
22. R. Demirtunc, D. Duman, M. Basar, M. Bilgi, M. Teomete, and T. Garip The relationship between glycemic control and platelet activity in type 2 diabetes mellitus J Diabetes Complications 23 2009 89 94
23. I.M. Stratton, A.I. Adler, H.A. Neil, D.R. Matthews, S.E. Manley, C.A. Cull, D. Hadden, R.C. Turner, and R.R. Holman Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ 32 2000 405 412
24. R.R. Holman, S.K. Paul, M.A. Bethel, D.R. Matthews, and H.A. Neil 10-Year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 359 2008 1577 1589
25. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N Engl J Med 329 1993 977 986
26. I.H. de Boer, W. Sun, P.A. Cleary, J.M. Lachin, M.E. Molitch, M.W. Steffes, and B. Zinman Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes N Engl J Med 365 2011 2366 2376
27. R. Boussageon, T. Bejan-Angoulvant, M. Saadatian-Elahi, D. Lafont, C. Bergeonneau, B. Kassai, S. Erpeldinger, J.M. Wright, F. Gueyffier, and C. Cornu Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials BMJ 343 2011 d4169
28. J.F. Polak, J.Y. Backlund, P.A. Cleary, A.P. Harrington, D.H. O'Leary, J.M. Lachin, and D.M. Nathan Progression of carotid artery intima-media thickness during 12 years in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study Diabetes 60 2011 607 613
29. J.L. Chiasson, R.G. Josse, R. Gomis, M. Hanefeld, A. Karasik, and M. Laakso Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial JAMA 290 2003 486 494
30. M. Hanefeld, M. Cagatay, T. Petrowitsch, D. Neuser, D. Petzinna, and M. Rupp Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies Eur Heart J 25 2004 10 16
31. J. Hong, Y. Zhang, S. Lai, A. Lv, Q. Su, Y. Dong, Z. Zhou, W. Tang, J. Zhao, L. Cui, D. Zou, D. Wang, H. Li, C. Liu, G. Wu, J. Shen, D. Zhu, W. Wang, W. Shen, and G. Ning Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease Diabetes Care 36 2013 1304 1311
32. H.C. Gerstein, M.E. Miller, R.P. Byington, D.C. Goff Jr., J.T. Bigger, J.B. Buse, W.C. Cushman, S. Genuth, F. Ismail-Beigi, R.H. Grimm, J.L. Probstfield, D.G. Simons-Morton, and W.T. Friedewald Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358 2008 2545 2559
33. A. Patel, S. MacMahon, J. Chalmers, B. Neal, L. Billot, M. Woodward, M. Marre, M. Cooper, P. Glasziou, D. Grobbee, P. Hamet, S. Harrap, S. Heller, L. Liu, G. Mancia, C.E. Mogensen, C. Pan, N. Poulter, A. Rodgers, B. Williams, S. Bompoint, B.E. de Galan, R. Joshi, and F. Travert Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 358 2008 2560 2572
34. W. Duckworth, C. Abraira, T. Moritz, D. Reda, N. Emanuele, P.D. Reaven, F.J. Zieve, J. Marks, S.N. Davis, R. Hayward, S.R. Warren, S. Goldman, M. McCarren, M.E. Vitek, W.G. Henderson, and G.D. Huang Glucose control and vascular complications in veterans with type 2 diabetes N Engl J Med 360 2009 129 139
35. M.C. Riddle Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial Circulation 122 2010 844 846
36. D.E. Bonds, M.E. Miller, R.M. Bergenstal, J.B. Buse, R.P. Byington, J.A. Cutler, R.J. Dudl, F. Ismail-Beigi, A.R. Kimel, B. Hoogwef, K.R. Horowitz, P.J. Savage, E.R. Seaquist, D.L. Simmons, W.I. Sivitz, J.M. Speril-Hillen, and M.E. Sweeney The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study BMJ 340 2010 b4909
37. G. Control, F.M. Turnbull, C. Abraira, R.J. Anderson, R.P. Byington, J.P. Chalmers, W.C. Duckworth, G.W. Evans, R.R. Holman, T.E. Moritz, B.C. Neal, T. Ninomiya, A.A. Patel, S.K. Paul, F. Travert, and M. Woodward Intensive glucose control and macrovascular outcomes in type 2 diabetes Diabetologia 52 2009 2288 2298
38. W.C. Knowler, S.E. Fowler, R.F. Hamman, C.A. Christophi, H.J. Hoffman, A.T. Brenneman, J.O. Brown-Friday, R. Goldberg, E. Venditti, and D.M. Nathan 10-Year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study Lancet 374 2009 1677 1686
39. W.C. Knowler, E. Barrett-Connor, S.E. Fowler, R.F. Hamman, J.M. Lachin, E.A. Walker, and D.M. Nathan Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N Engl J Med 346 2002 393 403
40. Look-AHEAD Research Group Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the Look AHEAD trial Diabetes Care 30 2007 1374 1383
41. Look-AHEAD Research Group Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial Arch Intern Med 170 2010 1566 1575
42. G.S. Papaetis, D. Orphanidou, and T.N. Panagiotou Thiazolidinediones and type 2 diabetes: from cellular targets to cardiovascular benefit Curr Drug Targets 12 2011 1498 1512
43. PROactive Investigators Group Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone clinical trial in macroVascular Events): a randomised controlled trial Lancet 366 2005 1279 1289
44. R.A. DeFronzo, D. Tripathy, D.C. Schwenke, M. Banerji, G.A. Bray, T.A. Buchanan, S.C. Clement, R.R. Henry, H.N. Hodin, A.E. Kitabchi, W.J. Mack, S. Mudaliar, R.E. Ratner, K. Williams, F.B. Stentz, N. Musi, and P.D. Reaven Pioglitazone for diabetes prevention in impaired glucose tolerance N Engl J Med 364 2011 1104 1115
45. A. Choy-Shan, A. Zinn, B. Shah, A. Danoff, R. Donnino, A. Schwartzbard, J.D. Lorin, E. Grossi, and S.P. Sedlis Effect of rosiglitazone on survival in patients with diabetes mellitus treated for coronary artery disease Coron Artery Dis 23 2012 354 358
46. NAVIGATOR Study Group Effect of nateglinide on the incidence of diabetes and cardiovascular events N Engl J Med 362 2010 1463 1476
47. M. Monami, I. Dicembrini, D. Martelli, and E. Mannucci Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials Curr Med Res Opin 27 Suppl 3 2011 S57 S64
48. J.H. Best, B.J. Hoogwerf, W.H. Herman, E.M. Pelletier, D.B. Smith, M. Wenten, and M.A. Hussain Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database Diabetes Care 34 2011 90 95
49. B.R. Peskin, A.V. Shcheprov, K.S. Boye, S. Bruce, D.G. Maggs, and J.A. Gaebler Cardiovascular outcomes associated with a new once-weekly GLP-1 receptor agonist vs. traditional therapies for type 2 diabetes: a simulation analysis Diabetes Obes Metab 13 2011 921 927
50. J.B. Buse, M. Nauck, T. Forst, W.H. Sheu, S.K. Shenouda, C.R. Heilmann, B.J. Hoogwerf, A. Gao, M.K. Boardman, M. Fineman, L. Porter, and G. Schernthaner Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study Lancet 381 2013 117 124
51. T. Vilsboll, M. Christensen, A.E. Junker, F.K. Knop, and L.L. Gluud Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials BMJ 344 2012 d7771
52. D.J. Drucker, J.B. Buse, K. Taylor, D.M. Kendall, M. Trautmann, D. Zhuang, and L. Porter Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study Lancet 372 2008 1240 1250
53. E.A. Schwartz, J. Koska, M.P. Mullin, I. Syoufi, D.C. Schwenke, and P.D. Reaven Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus Atherosclerosis 212 2010 217 222